Your session is about to expire
← Back to Search
Vitamin
Vitamin D for COVID-19 Prevention
N/A
Waitlist Available
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects are 18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
Study Summary
This trial is testing if different doses of vitamin D can help prevent people from getting COVID-19 or make the illness less severe.
Who is the study for?
This trial is for adults over 18 living or working in the Chicagoland area who are interested in using vitamin D to prevent COVID-19. They must be willing to take daily doses of vitamin D, attend quarterly blood tests, and complete surveys throughout the 9-month study. People with certain medical conditions like hyperparathyroidism, kidney stones, or high calcium levels can't join.Check my eligibility
What is being tested?
The study aims to see if different doses of Vitamin D (low at 400 IU/day vs. moderate at 4,000 IU/day vs. high at 10,000 IU/day) affect the risk of getting COVID-19 among participants from Chicago communities over a period of nine months.See study design
What are the potential side effects?
Potential side effects may include elevated calcium levels which could lead to kidney stones or digestive issues; however, these risks are generally low and will be monitored through regular blood tests during the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9-months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9-months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Inverse PCR
Secondary outcome measures
SARS-CoV-2 antibody seroconversion confirmed by a COVID-19 antibody test
Other outcome measures
Death following COVID-19
Hospitalization following COVID-19
ICU stay following COVID-19
+1 moreTrial Design
3Treatment groups
Active Control
Group I: Low Dose Vitamin DActive Control1 Intervention
Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
Group II: Medium Dose Vitamin DActive Control1 Intervention
Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
Group III: High Dose Vitamin DActive Control1 Intervention
Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,001 Previous Clinical Trials
815,730 Total Patients Enrolled
11 Trials studying COVID-19
33,108 Patients Enrolled for COVID-19
Rush University Medical CenterOTHER
422 Previous Clinical Trials
161,531 Total Patients Enrolled
5 Trials studying COVID-19
18,452 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am willing to complete surveys about my health over 9 months.I am willing to take vitamin D daily for 9 months to prevent COVID-19.I have a history of hyperparathyroidism.I have had kidney stones before (1 in the last year or 2 ever).I take more than 400 IU of vitamin D daily, not including multivitamins or combined with calcium.You have taken the medication D2.I am not willing to take daily vitamin D supplements.I am 18 years old or older.You have had a positive COVID-19 test.I have a history of chronic kidney disease.I have a history of falling more often than usual.You have had high levels of calcium in your blood in the past.Your blood tests show that you have too much calcium in your blood.I have had surgery to help with weight loss or have a condition that affects how my body absorbs food.Your vitamin D levels are too high at the start of the study or during follow-up tests.You have COVID-19 antibodies in your blood when you are tested at the beginning.Your initial blood test shows that you have primary hyperparathyroidism.I have a history of sarcoidosis.
Research Study Groups:
This trial has the following groups:- Group 1: Low Dose Vitamin D
- Group 2: Medium Dose Vitamin D
- Group 3: High Dose Vitamin D
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many individuals have registered to participate in this research?
"Affirmative. This medical study, which was originally published on November 30th 2020, is presently seeking eligible participants. 2000 patients must be enrolled from 2 distinct healthcare institutions."
Answered by AI
Is the enrollment for this research still open?
"Affirmative, the clinicaltrial.gov records demonstrate that this scientific trial is currently enrolling participants. The project was initially shared on November 30th 2020 and last revised on April 26th 2021. 2000 patients need to be recruited from 2 medical sites."
Answered by AI
Who else is applying?
What site did they apply to?
University of Chicago
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger